{"id":"pyrotinib-plus-capecitabine","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Hand-foot syndrome"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pyrotinib works by binding to the HER2/neu receptor, preventing its activation and subsequent signaling pathways that promote cell growth and survival. Capecitabine, on the other hand, is converted into fluorouracil, which is then phosphorylated into fluorodeoxyuridine monophosphate (FdUMP) and fluorodeoxyuridine triphosphate (FdUTP). These metabolites inhibit thymidylate synthase, leading to the depletion of thymidine and ultimately, cell death.","oneSentence":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while capecitabine is a prodrug of fluorouracil, an antimetabolite that interferes with DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:53.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic breast cancer with HER2 overexpression"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07417241","phase":"PHASE2","title":"SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT05424835","phase":"PHASE3","title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-04","conditions":"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","enrollment":381},{"nctId":"NCT06027541","phase":"","title":"Young Patients With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08-01","conditions":"Breast Cancer Female","enrollment":1000},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT07019337","phase":"PHASE2","title":"Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-30","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT06754059","phase":"","title":"Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC","status":"RECRUITING","sponsor":"zhangjie","startDate":"2021-06-01","conditions":"HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT06483386","phase":"PHASE2","title":"Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-15","conditions":"Breast Cancer","enrollment":109},{"nctId":"NCT06481553","phase":"","title":"RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-02-01","conditions":"Breast Cancer Stage IV","enrollment":480},{"nctId":"NCT06475443","phase":"PHASE2","title":"Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-06-15","conditions":"Metastatic Breast Cancer in the Brain","enrollment":32},{"nctId":"NCT06217185","phase":"PHASE4","title":"The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-02","conditions":"HER2-positive Breast Cancer, Advanced Breast Cancer","enrollment":100},{"nctId":"NCT05575804","phase":"PHASE1, PHASE2","title":"GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-10-01","conditions":"Advanced/ Metastatic Her-2 Positive Breast Cancer","enrollment":75},{"nctId":"NCT05042791","phase":"PHASE2","title":"A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases","status":"UNKNOWN","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2022-03-01","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":362},{"nctId":"NCT04395989","phase":"PHASE2","title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-07-28","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":139},{"nctId":"NCT06152822","phase":"PHASE2","title":"Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-11-30","conditions":"Breast Cancer With Brain Metastases","enrollment":30},{"nctId":"NCT03691051","phase":"PHASE2","title":"A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-11-20","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT06035016","phase":"","title":"Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-06-01","conditions":"HER2-positive Breast Cancer, Early-stage Breast Cancer","enrollment":300},{"nctId":"NCT04582968","phase":"PHASE1, PHASE2","title":"Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-01-02","conditions":"Breast Cancer, Brain Metastases, HER2-positive Breast Cancer","enrollment":39},{"nctId":"NCT04001621","phase":"PHASE2","title":"Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-06-26","conditions":"Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT02973737","phase":"PHASE3","title":"A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-07-20","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":279},{"nctId":"NCT05359120","phase":"","title":"Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-30","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03805399","phase":"PHASE1, PHASE2","title":"FUSCC Refractory TNBC Umbrella (FUTURE)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-10-18","conditions":"Triple-negative Breast Cancer","enrollment":140},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT04850625","phase":"","title":"Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-01-15","conditions":"Breast Cancer","enrollment":224},{"nctId":"NCT04769050","phase":"","title":"Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-18","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT05292742","phase":"PHASE2","title":"Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2021-07-02","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":206},{"nctId":"NCT05255523","phase":"PHASE2","title":"Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2022-02-20","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05111444","phase":"PHASE2","title":"Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12-31","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":65},{"nctId":"NCT04681911","phase":"PHASE2","title":"Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-09-09","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT04646759","phase":"PHASE3","title":"Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-10-14","conditions":"Breast Cancer","enrollment":516},{"nctId":"NCT03080805","phase":"PHASE3","title":"Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-05-03","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT04246502","phase":"PHASE2","title":"Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-01","conditions":"Metastatic Breast Cancer","enrollment":200},{"nctId":"NCT04227041","phase":"PHASE1, PHASE2","title":"A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer","status":"UNKNOWN","sponsor":"Qingdao Zhixin Health Technology Co., Ltd.","startDate":"2020-01-10","conditions":"HER-2 Positive Colorectal Cancer","enrollment":34},{"nctId":"NCT04095390","phase":"PHASE2","title":"A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2019-09-30","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT03923166","phase":"PHASE2","title":"Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-04-19","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT02361112","phase":"PHASE1","title":"Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-08","conditions":"Metastatic Breast Cancer","enrollment":38},{"nctId":"NCT02422199","phase":"PHASE1, PHASE2","title":"A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-05","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SHR1258","Irene"],"phase":"phase_3","status":"active","brandName":"pyrotinib plus capecitabine","genericName":"pyrotinib plus capecitabine","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while capecitabine is a prodrug of fluorouracil, an antimetabolite that interferes with DNA synthesis. Used for Advanced or metastatic breast cancer with HER2 overexpression, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}